ABVC (ABVC BioPharma, Inc.) Future Price to Earnings
Flexible asset management and global trials at ABVC BioPharma are creating intrigue surrounding the business valuation. The company's consensus P/E forecast helps track valuation anomalies, where 0.00 shows the current value of the metric. AI-driven laboratory robotics and a plant-based drug licensing strategy, which allows the company to avoid direct price wars in the market, provide the foundation for stability.
Summary analytical data breakdowns for ABVC BioPharma, Inc (ABVC)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital ABVC BioPharma|ABVC - Long-Term Liabilities to Capital|Short-Term Debt to Equity ABVC BioPharma|ABVC - Aggregate Debt Obligations|Debts to Book Capitalization ABVC BioPharma Inc.|ABVC - Company Long-Term Debts|Company Short-Term Debts ABVC BioPharma|Quick Liquidity Indicator abvcpharma.com
- financial results and valuation multiples details:
ABVC - Company Net Income|Projected Future Earnings ABVC BioPharma|ABVC - Price to Earnings Ratio|Projected Price to Earnings ABVC BioPharma Inc|ABVC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ABVC BioPharma Inc.|ABVC - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) ABVC BioPharma|ABVC - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months abvcpharma.com|ABVC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ABVC BioPharma
Fundamental valuation:ABVC BioPharma, Inc.
The resilience of ABVC BioPharma (ABVC) against pressure from pharmaceutical behemoths in the natural products niche depends on the precise execution of its financial plans. By analyzing the company's forward P/E ratio, an investor assesses the current market value of the business relative to expected net income, where an inflated multiple signals a risk of correction, while an excessively low one indicates potential stagnation of investment capital.
Analysis of competing companies
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals, Inc.)|Forward P/E Multiple Pacira Pharmaceuticals PCRX|ARS Pharma - Forward P/E Multiple|TBPH: Future Price to Earnings|AQST (Aquestive Therapeutics) - Projected Price to Earnings|SCPH (scPharmaceuticals) - Future Price to Earnings|TECX (Tectonic Therapeutic Inc.) - Forward P/E Multiple|Projected Price to Earnings Tonix Pharma (TNXP)|Projected Price to Earnings SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Future Price to Earnings Multiple|Forward P/E Multiple BHST (BioHarvest Sciences)|invizyne.com - Future Price to Earnings|Oramed Pharma - Forward P/E Multiple|Market Cap to Projected Earnings Entera Bio Ltd. ENTX|MindWalk (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio Cumberland Corp (CPIX)|Future Price to Earnings Quantum BioPharma Ltd|fibrogen.com - Price to Expected Earnings Ratio|Forward P/E Multiple TELO|RANI (ranitherapeutics.com) - Future Price to Earnings Multiple|Forward P/E Multiple SNYR (Synergy CHC)|Forward P/E Multiple Rallybio Corp RLYB|LEXX - Future Price to Earnings|Future Price to Earnings Multiple PULM (pulmatrix.com)|ftzy.com.cn (PTHL) - Future Price to Earnings|Projected Price to Earnings Aptorum Group|LYRA (Lyra Therapeutics, Inc) - Forward P/E Multiple|Forward P/E Multiple Impact BioMedical, Inc.|Forward P/E Multiple TNFA|Forward P/E Multiple cbdmd.com (YCBD)|Forward P/E Multiple PRFX (PainReform)|Altamira Therapeutics Ltd - Future Price to Earnings|LIPO: Projected Price to Earnings|OPTN: Future Price to Earnings|PIRS: Forward P/E Multiple|Projected Price to Earnings procapsgroup.com|Future Price to Earnings Petros Pharmaceuticals, Inc.|Qilian International Holding Group - Price to Expected Earnings Ratio|Forward P/E Multiple SLRN|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Earnings Multiple
